NCT01046422

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

A Double-blind, Placebo-Controlled, Parallel-group, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of BMS-770767 in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Either Diet and Exercise Alone or on a Background of Metformin

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 76 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if BMS-770767 is safe, well tolerated, measure its levels in the blood (pharmacokinetics), and measure the levels of chemicals (biomarkers) that may be affected by this drug (pharmacodynamics) in a type 2 diabetes patient population

Conditions

• Diabetes Type 2

Interventions

Type	Name	Description
DRUG	BMS-770767	Capsule, Oral, 15mg, Active, Daily, 28 days
DRUG	BMS-770767	Capsule, Oral, 50mg, Active, Daily, 28 days
DRUG	BMS-770767	Capsule, Oral, 150mg, Active, Daily, 28 days
DRUG	BMS-770767	Capsule, Oral, 50mg BID, Active, Daily, 28 days
DRUG	Placebo	Capsule, Oral, 0mg, Daily, 28 days
DRUG	Metformin	Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days

Timeline

• Start date: 2010-05-01
• Primary completion: 2011-01-01
• Completion: 2011-01-01
• First posted: 2010-01-12
• Last updated: 2015-10-12

Locations

18 sites across 4 countries: United States, Australia, Canada, South Korea